Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Documenti analoghi

• Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
  di: Stopeck, Alison T., et al.
  Pubblicazione: (2015)
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
  di: Fizazi, Karim, et al.
  Pubblicazione: (2011)
• Denosumab and Bone Metastasis-Free Survival in Men With Castration-Resistant Prostate Cancer: Results of a Global Phase 3, Randomised, Placebo-Controlled Trial
  di: Smith, Matthew R, et al.
  Pubblicazione: (2011)
• Impact of denosumab on bone mass in cancer patients
  di: Brown-Glaberman, Ursa, et al.
  Pubblicazione: (2013)
• Response to letter to the Editors—Safety of long-term denosumab therapy
  di: Stopeck, Alison T., et al.
  Pubblicazione: (2016)